English Polski

Advanced search

  • Acta Angiologica
  • Vol 27, No 3 (2021) Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age
Vol 27, No 3 (2021)
Guidelines / Expert consensus
Published online: 2021-12-30

open access

View PDF Download PDF file
Page views 7018
Article views/downloads 12890
Get Citation

Connect on Social Media

Connect on Social Media

The content of this article is also available in the following languages:
Polski

Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age

Zbigniew Krasiński, Tomasz Urbanek, Anetta Undas, Joanna Rupa-Matysek, Aleksander Araszkiewicz, Katarzyna Derwich, Aneta Klotzka, Artur Antoniewicz, Beata Begier-Krasińska, Cezary Piwkowski, Tomasz Banasiewicz, Marcin Gabriel, Piotr Ładziński, Witold Tomkowski, Dawid Murawa, Rodryg Ramlau, Piotr Rutkowski, Piotr Pruszczyk, Filip M. Szymański, Andrzej Szuba, Tomasz Zubilewicz, Stefan Sajdak, Jerzy Windyga
DOI: 10.5603/AA.2021.0006
Acta Angiologica 2021;27(3):81-112.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78(5): 285–291.
    CrossRefPubMed
  2. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
    CrossRefPubMed
  3. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3): 632–634.
    CrossRefPubMed
  4. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016; 41(1): 3–14.
    CrossRefPubMed
  5. Urbanek T, Krasiński Z, Kostrubiec M, et al. Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients. Acta Angiologica. 2017; 22(3): 71–102.
    CrossRef
  6. http://www.g-i-n.net.
  7. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4(19): 4693–4738.
    CrossRefPubMed
  8. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019; 3(23): 3898–3944.
    CrossRefPubMed
  9. Kakkos SK, Gohel M, Baekgaard N, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021; 61(1): 9–82.
    CrossRefPubMed
  10. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38(5): 496–520.
    CrossRefPubMed
  11. Farge D, Frere C, Connors J, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. 2019; 20(10): e566–e581.
    CrossRef
  12. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007; 147(4): 224–233.
    CrossRefPubMed
  13. Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice – Management of Chronic Venous Disease. European Journal of Vascular and Endovascular Surgery. 2015; 49(6): 678–737.
    CrossRef
  14. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.
    CrossRefPubMed
  15. Rabe E, Partsch H, Hafner J, et al. Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. Phlebology. 2018; 33(3): 163–184.
    CrossRefPubMed
  16. Kahn SR, Comerota AJ, Cushman M, et al. American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014; 130(18): 1636–1661.
    CrossRefPubMed
  17. Guyatt G, Oxman A, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008; 336(7652): 1049–1051.
    CrossRef
  18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924–926.
    CrossRefPubMed
  19. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): 53S–70S.
    CrossRefPubMed
  20. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014; 8: 129–137.
    CrossRefPubMed
  21. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013; 11(1): 56–70.
    CrossRefPubMed
  22. Lyman GH, Bohlke K, Falanga A, et al. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015; 11(3): e442–e444.
    CrossRefPubMed
  23. Mandalà M, Falanga A, Roila F, et al. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6: vi85–vi92.
    CrossRefPubMed
  24. Gould MK, Garcia DA, Wren SM, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e185S–e194S.
    CrossRefPubMed
  25. Zawilska K, Bała M, Błędowski P, et al. Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update. Polish Archives of Internal Medicine. 2012; 122(Suppl. 2): 1–76.
    CrossRef
  26. Akl EA, Muti P, Schünemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008; 118(4): 183–193.
    PubMed
  27. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. The American Journal of Surgery. 1970; 120(4): 527–530.
    CrossRef
  28. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992; 11(3-4): 237–248.
    CrossRefPubMed
  29. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8): 464–474.
    CrossRefPubMed
  30. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2): 62–69.
    CrossRefPubMed
  31. Wun T, White RH, Ku GH, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009; 113(17): 3911–3917.
    CrossRefPubMed
  32. Pellino G, Sciaudone G, Candilio G, et al. Predictors of Venous Thromboembolism after Colorectal Surgery in a Single Unit. Acta Chir Belg. 2015; 115(4): 288–292.
    CrossRefPubMed
  33. Kucher N, Spirk D, Baumgartner I, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol. 2010; 21(5): 931–935.
    CrossRefPubMed
  34. Lyman GH. Thromboprophylaxis with low-molecular--weight heparin in medical patients with cancer. Cancer. 2009; 115: 5637.
  35. Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol. 2007; 96(3): 265–272.
    CrossRefPubMed
  36. Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6): 809–815.
    CrossRefPubMed
  37. Nijziel MR, van Oerle R, Hillen HFP, et al. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med. 2006; 64(11): 403–410.
    PubMed
  38. Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015; 22(2): 133–143.
    CrossRefPubMed
  39. Caprini JA, Arcelus JI, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991; 17 Suppl 3: 304–312.
    PubMed
  40. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51(2-3): 70–78.
    CrossRefPubMed
  41. Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not? Hamostaseologie. 2015; 35(4): 319–324.
    CrossRefPubMed
  42. Bouras G, Burns EM, Howell AM, et al. Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England. PLoS One. 2015; 10(12): e0145759.
    CrossRefPubMed
  43. NICE guidance: Venous thromboembolism: reducing the risk: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital [CG92]. https://www.nice.org.uk/guidance/cg92..
  44. Törngren S, Rieger A. Prophylaxis of deep venous thrombosis in colorectal surgery. Dis Colon Rectum. 1982; 25(6): 563–566.
    CrossRefPubMed
  45. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 338S–400S.
    CrossRefPubMed
  46. Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011; 254(1): 131–137.
    CrossRefPubMed
  47. Alsubaie H, Leggett C, Lambert P, et al. Diagnosis of VTE postdischarge for major abdominal and pelvic oncologic surgery: implications for a change in practice. Can J Surg. 2015; 58(5): 305–311.
    CrossRefPubMed
  48. Larsen AC, Frøkjær JB, Fisker RV, et al. Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors. Thromb Res. 2015; 135(5): 802–808.
    CrossRefPubMed
  49. Lodders JN, Parmar S, Stienen NLM, et al. Incidence of symptomatic venous thromboembolism in oncological oral and maxillofacial operations: retrospective analysis. Br J Oral Maxillofac Surg. 2015; 53(3): 244–250.
    CrossRefPubMed
  50. Chiesa Estomba C, Rivera Schmitz T, Ossa Echeverri CC, et al. The risk of venous thromboembolism in ENT and head & neck surgery. Otolaryngol Pol. 2015; 69(3): 31–36.
    CrossRefPubMed
  51. Kakei Y, Akashi M, Hasegawa T, et al. Incidence of Venous Thromboembolism After Oral Oncologic Surgery With Simultaneous Reconstruction. J Oral Maxillofac Surg. 2016; 74(1): 212–217.
    CrossRefPubMed
  52. Tran BH, Nguyen TJ, Hwang BH, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast. 2013; 22(4): 444–448.
    CrossRefPubMed
  53. De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012; 55(4): 1035–1040.e4.
    CrossRefPubMed
  54. Lovely JK, Nehring SA, Boughey JC, et al. Balancing venous thromboembolism and hematoma after breast surgery. Ann Surg Oncol. 2012; 19(10): 3230–3235.
    CrossRefPubMed
  55. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208(2): 227–240.
    CrossRefPubMed
  56. Wille-Jorgensen P. Prophylaxis of postoperative deep venous thrombosis. JAMA: The Journal of the American Medical Association. 1985; 253(8): 1120b-1120.
    CrossRef
  57. Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986; 73(3): 204–208.
    CrossRefPubMed
  58. Bergqvist D, Mätzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988; 75(9): 888–891.
    CrossRefPubMed
  59. Samama M, Bernard P, Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988; 75(2): 128–131.
    CrossRefPubMed
  60. Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of postoperative deep vein thrombosis in general surgery: a multicenter double-blind study comparing two doses of logiparin and standard heparin. Br J Surg. 1991; 78: 412–416.
  61. Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis. 1993; 4 Suppl 1: S21–S22.
    PubMed
  62. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomi¬zed multicentre trial with venographic assessment. Br J Surg; 84: 1099–1103.
  63. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet. 1993; 341(8840): 259–265.
    CrossRefPubMed
  64. The European Fraxiparin Study (EFS) Group (1988) Compari¬son of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg; 75: 1058–1063.
  65. Baykal C, Al A, Demirtaş E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001; 22(2): 127–130.
    PubMed
  66. Akl EA, Kahale L, Sperati F, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev. 2014(6): CD009447.
    CrossRefPubMed
  67. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. British Journal of Surgery. 2005; 82(4): 496–501.
    CrossRef
  68. Kakkar AK, Agnelli G, George D et al (2011) The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, 2011, December 10–13, 2011 2011.
  69. Simonneau G, Laporte S, Mismetti P, et al. FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006; 4(8): 1693–1700.
    CrossRefPubMed
  70. Agnelli G, Bergqvist D, Cohen AT, et al. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005; 92(10): 1212–1220.
    CrossRefPubMed
  71. Yamaoka Y, Ikeda M, Ikenaga M, et al. Safety and efficacy of fondaparinux for prophylaxis of venous thromboembolism after colorectal cancer resection: a propensity score matched analysis. Dig Surg. 2015; 32(3): 190–195.
    CrossRefPubMed
  72. Yasui M, Ikeda M, Miyake M, et al. Clinical Study Group of Osaka University (CSGO), Colorectal Group. Comparison of bleeding risks related to venous thromboembolism prophylaxis in laparoscopic vs open colorectal cancer surgery: a multicenter study in Japanese patients. Am J Surg. 2017; 213(1): 43–49.
    CrossRefPubMed
  73. Kimura Y, Oki E, Ando K, et al. Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Single-Center, Prospective Cohort Study. World J Surg. 2016; 40(2): 309–314.
    CrossRefPubMed
  74. Xie YZ, Fang K, Ma WL, et al. Risk of postoperative deep venous thrombosis in patients with colorectal cancer treated with open or laparoscopic colorectal surgery: a meta-analysis. Indian J Cancer. 2015; 51 Suppl 2: e42–e44.
    CrossRefPubMed
  75. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee. Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Surg Endosc. 2007; 21(6): 1007–1009.
    CrossRefPubMed
  76. Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014; 259(4): 665–669.
    CrossRefPubMed
  77. Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2016; 23(5): 1422–1430.
    CrossRefPubMed
  78. Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2018; 11: CD004318.
    CrossRefPubMed
  79. Bustos Merlo AB, Arcelus Mart ınez JI, Turi o Luque JD, et al. Form of presentation, natural history and course of postoperative venous thromboembolism in patients operated on for pelvic and abdominal cancer. Analysis of the RIETE registry. Cir Esp 95: 328-334, 2017.
  80. Guo Q, Huang B, Zhao J, et al. Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2017; 265(6): 1087–1093.
    CrossRefPubMed
  81. Carrier M, Altman AD, Blais N, et al. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. Am J Surg. 2019; 218(3): 537–550.
    CrossRefPubMed
  82. Schomburg J, Krishna S, Soubra A, et al. Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. Urol Oncol. 2018; 36(2): 77.e9–77.e13.
    CrossRefPubMed
  83. Pariser JJ, Pearce SM, Anderson BB, et al. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin. J Urol. 2017; 197(2): 302–307.
    CrossRefPubMed
  84. Kim BJ, Day RW, Davis CH, et al. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost. 2017; 15(11): 2158–2164.
    CrossRefPubMed
  85. Bergqvist D, Agnelli G, Cohen AT, et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346(13): 975–980.
    CrossRefPubMed
  86. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006; 4(11): 2384–2390.
    CrossRefPubMed
  87. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res. 2010; 125(3): e65–e70.
    CrossRefPubMed
  88. Nagata C, Tanabe H, Takakura S, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015; 41(9): 1440–1448.
    CrossRefPubMed
  89. Song KY, Yoo HMo, Kim EY, et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Ann Surg Oncol. 2014; 21(13): 4232–4238.
    CrossRefPubMed
  90. Wang Jp, Lin Yd, Wang L, et al. [Effect of intermittent pneumatic compression on coagulation function and deep venous hemodynamics of lower limbs after rectal cancer resection]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16(8): 739–743.
    PubMed
  91. Ramirez JI, Vassiliu P, Gonzalez-Ruiz C, et al. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg. 2003; 69(11): 941–945.
    PubMed
  92. Zareba P, Wu C, Agzarian J, et al. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. Br J Surg. 2014; 101(9): 1053–1062.
    CrossRefPubMed
  93. Jung YJu, Seo HoS, Park CH, et al. Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial. JAMA Surg. 2018; 153(10): 939–946.
    CrossRefPubMed
  94. Nagata C, Tanabe H, Takakura S, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015; 41(9): 1440–1448.
    CrossRefPubMed
  95. Dong J, Wang J, Feng Y, et al. Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer. J Thorac Dis. 2018; 10(3): 1850–1856.
    CrossRefPubMed
  96. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110(10): 2339–2346.
    CrossRefPubMed
  97. Vitale C, D'Amato M, Calabrò P, et al. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015; 10(1): 28.
    CrossRefPubMed
  98. Zhang Y, Yang Y, Chen W, et al. China Venous Thromboembolism VTE Study Group, China Venous Thromboembolism (VTE) Study Group. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest. 2014; 146(3): 650–658.
    CrossRefPubMed
  99. Steuer CE, Behera M, Kim S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015; 88(1): 80–84.
    CrossRefPubMed
  100. Yu Y, Lv Q, Zhang B, et al. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Cancer Res Ther. 2016; 12(Supplement): 37–42.
    CrossRefPubMed
  101. Fuentes HE, Oramas DM, Paz LH, et al. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res. 2017; 154: 28–34.
    CrossRefPubMed
  102. Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016; 151(1): 37–44.e1.
    CrossRefPubMed
  103. Sterbling HM, Rosen AK, Hachey KJ, et al. Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients. Ann Thorac Surg. 2018; 105(3): 879–885.
    CrossRefPubMed
  104. Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2016; 27(3): 270–274.
    CrossRefPubMed
  105. Salmaggi A, Simonetti G, Trevisan E, et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. J Neurooncol. 2013; 113(2): 293–303.
    CrossRefPubMed
  106. Collen JF, Jackson JL, Shorr AF, et al. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest. 2008; 134(2): 237–249.
    CrossRefPubMed
  107. Hamilton MG, Yee WH, Hull RD, et al. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. Neurosurgery. 2011; 68(3): 571–581.
    CrossRefPubMed
  108. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997; 33(10): 1592–1596.
    CrossRefPubMed
  109. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89(3): 640–646, doi: 10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e.
    PubMed
  110. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983; 13(3): 334–336.
    CrossRefPubMed
  111. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. 2001; 7(5): 326–331.
    CrossRefPubMed
  112. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; 106(4): 601–608.
    CrossRefPubMed
  113. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010; 8(2): 221–227.
    CrossRefPubMed
  114. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015; 124(1): 87–94.
    CrossRefPubMed
  115. Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999; 8(2): 139–142.
    CrossRefPubMed
  116. Kimmell KT, Walter KA. Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease. J Neurooncol. 2014; 120(3): 567–573.
    CrossRefPubMed
  117. Turpie AG, Gallus A, Beattie WS, et al. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 1977; 27(5): 435–438.
    CrossRefPubMed
  118. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery. 1978; 83(3): 354–358.
    PubMed
  119. Bucci M, Papadopoulos S, Chen J, et al. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: A randomized trial. Surgical Neurology. 1989; 32(4): 285–288.
    CrossRef
  120. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998; 339(2): 80–85.
    CrossRefPubMed
  121. Turpie AG, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. 1989; 149(3): 679–681.
    PubMed
  122. Wautrecht JC, Macquaire V, Vandesteene A et al (1996) Prevention of deep vein thrombosis in neurosurgical patients withbrain tumors: a controlled, randomized study comparing graded compression stockings alone and with intermittent sequential compression: correlation with pre- and post-operative fibrinolysis; preliminary results. Int Angiol; 15 (suppl 1): 5–10.
  123. Sobieraj-Teague M, Hirsh J, Yip G, et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. J Thromb Haemost. 2012; 10(2): 229–235.
    CrossRefPubMed
  124. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000; 160(15): 2327–2332.
    CrossRefPubMed
  125. Khaldi A, Helo N, Schneck MJ, et al. Venous thromboembolism: deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011; 114(1): 40–46.
    CrossRefPubMed
  126. Dickinson LD, Miller LD, Patel CP, et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 1998; 43(5): 1074–1081.
    CrossRefPubMed
  127. Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost. 1996; 75(2): 233–238.
    PubMed
  128. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978; 49(3): 378–381.
    CrossRefPubMed
  129. Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg. 2001; 94(6): 918–921.
    CrossRefPubMed
  130. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 2002; 122(6): 1933–1937.
    CrossRefPubMed
  131. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 2003; 59(5): 363–72; discussion 372.
    CrossRefPubMed
  132. Glotzbecker MP, Bono CM, Wood KB, et al. Thromboembolic disease in spinal surgery: a systematic review. Spine (Phila Pa 1976). 2009; 34(3): 291–303.
    CrossRefPubMed
  133. Samama CM, Albaladejo P, Benhamou D, et al. Committee for Good Practice Standards of the French Society for Anaesthesiology and Intensive Care (SFAR). Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol. 2006; 23(2): 95–116.
    CrossRefPubMed
  134. Nicolaides AN, Fareed J, Kakkar AK, et al. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20(1): 1–37.
    PubMed
  135. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9): 1079–1095.
    CrossRefPubMed
  136. Forrest JB, Clemens JQ, Finamore P, et al. American Urological Association. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009; 181(3): 1170–1177.
    CrossRefPubMed
  137. Colby FH. The prevention of fatal pulmonary emboli after prostatectomy. J Urol. 1948; 59(5): 920–4; Disc., 925.
    CrossRefPubMed
  138. Gordon-Smith IC, Hickman JA, el-Masri SH. The efect of the fibrinolytic inhibitor epsilonaminocaproic amid on the incidence of deep-vein thrombosis after prostatectomy. Br J Surg. 1972; 59: 599.
  139. Nicolaides AN, Field ES, Kakkar VV, et al. Prostatectomy and deep-vein thrombosis. Br J Surg. 1972; 59(6): 487–488.
    CrossRefPubMed
  140. Thomas PJ, Nurse DE, Deliveliotis C, et al. Cystoprostatectomy and substitution cystoplasty for locally invasive bladder cancer. Br J Urol. 1992; 70(1): 40–42.
    CrossRefPubMed
  141. Alberts BD, Woldu SL, Weinberg AC, et al. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology. 2014; 84(4): 799–806.
    CrossRefPubMed
  142. Potretzke AM, Wong KS, Shi F, et al. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann. 2015; 7(3): 355–360.
    CrossRefPubMed
  143. VanDlac AA, Cowan NG, Chen Y, et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol. 2014; 191(4): 943–947.
    CrossRefPubMed
  144. Rosario DJ, Becker M, Anderson JB. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int. 2000; 85(4): 427–430.
    CrossRefPubMed
  145. James AC, Holt SK, Wright JL, et al. Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. Urol Oncol. 2014; 32(6): 815–819.
    CrossRefPubMed
  146. White RH, Zhou H, Gage BF, et al. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 90(3): 446–455.
    CrossRefPubMed
  147. Heinzer H, Hammerer P, Graefen M, et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol. 1998; 33(1): 86–90.
    CrossRefPubMed
  148. Leibovitch I, Foster R, Wass J, et al. Color Doppler Flow Imaging For Deep Venous Thrombosis Screening in Patients Undergoing Pelvic Lymphadenectomy and Radical Retropubic Prostatectomy for Prostatic Carcinoma. The Journal of Urology. 1995: 1866–1869.
    CrossRef
  149. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: Morbidity and urinary continence in 418 consecutive cases. Urology. 1994; 43: 47–51.
    CrossRef
  150. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992; 147(3 Pt 2): 883–887.
    CrossRefPubMed
  151. Pedersen K, Herder A. Radical Retropubic Prostatectomy for Localised Prostatic Carcinoma: A Clinical and Pathological Study of 201 Cases. Scand J Urol Nephrol. 1993; 27(2): 219–224.
    CrossRef
  152. Shekarriz B, Upadhyay J, Wood DP. Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am. 2001; 28(3): 639–643.
    CrossRefPubMed
  153. Andriole GL, Smith DS, Rao G, et al. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol. 1994; 152(5 Pt 2): 1858–1860.
    CrossRefPubMed
  154. Dillioglugil O, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997; 157(5): 1760–1767.
    PubMed
  155. Lerner SE, Blute ML, Lieber MM, et al. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995; 9(5): 379–82; discussion 382, 385.
    PubMed
  156. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999; 162(2): 433–438.
    PubMed
  157. Hammond J, Kozma C, Hart JC, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol. 2011; 18(12): 3240–3247.
    CrossRefPubMed
  158. Beyer J, Wessela S, Hakenberg OW, et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. J Thromb Haemost. 2009; 7(4): 597–604.
    CrossRefPubMed
  159. Chan SYS, Leung VFY, Yee CH, et al. Incidence of postoperative deep vein thrombosis after robotic-assisted laparoscopic prostatectomy: a prospective study in Chinese patients. Int Urol Nephrol. 2014; 46(11): 2139–2142.
    CrossRefPubMed
  160. Streiff MB, Bockenstedt PL, Cataland SR, et al. National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013; 11(11): 1402–1429.
    CrossRefPubMed
  161. Pettus JA, Eggener SE, Shabsigh A, et al. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006; 68(5): 988–992.
    CrossRefPubMed
  162. Smith AB, Horvath-Puhó E, Nielsen ME, et al. Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma. Urol Oncol. 2014; 32(4): 466–472.
    CrossRefPubMed
  163. Ihaddadene R, Yokom DW, Le Gal G, et al. The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. J Thromb Haemost. 2014; 12(6): 855–859.
    CrossRefPubMed
  164. Yokom DW, Ihaddadene R, Moretto P, et al. Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. J Thromb Haemost. 2014; 12(2): 169–171.
    CrossRefPubMed
  165. Kavoussi L, Sosa E, Chandhoke P, et al. Complications of Laparoscopic Pelvic Lymph Node Dissection. Journal of Urology. 1993; 149(2): 322–325.
    CrossRef
  166. Caddedu JA, Wolf JS, Nakada S. Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol. 2001; 166: 2109–2111.
  167. Fahlenkamp D, Rassweiler J, Fornara P, et al. Complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 German centers. J Urol. 1999; 162(3 Pt 1): 765–70; discussion 770.
    CrossRefPubMed
  168. Rassweiler JJ, Seemann O, Frede T, et al. Retroperitoneoscopy: experience with 200 cases. J Urol. 1998; 160(4): 1265–1269.
    CrossRefPubMed
  169. Trabulsi EJ, Guillonneau B, Touijer K, et al. Laparoscopic radical prostatectomy: a review of techniques and results worldwide. Minerva Urol Nefrol. 2003; 55(4): 239–250.
    PubMed
  170. Montgomery JS, Wolf JS. Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. J Urol. 2005; 173(5): 1623–1626.
    CrossRefPubMed
  171. Permpongkosol S, Link RE, Su LM, et al. Complications of 2,775 urological laparoscopic procedures: 1993 to 2005. J Urol. 2007; 177(2): 580–585.
    CrossRefPubMed
  172. Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008; 53(1): 134–145.
    CrossRefPubMed
  173. Chalmers D, Scarpato K, Staff I, et al. Does Heparin Prophylaxis Reduce the Risk of Venous Thromboembolism in Patients Undergoing Robot-Assisted Prostatectomy? Journal of Endourology. 2013; 27(6): 800–803.
    CrossRef
  174. Patel T, Kirby W, Hruby G, et al. Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int. 2011; 108(5): 729–732.
    CrossRefPubMed
  175. Abel EJ, Wong K, Sado M, et al. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014; 18(2): 282–287.
    CrossRefPubMed
  176. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
    CrossRefPubMed
  177. Kibel A, Loughlin K. Pathogenesis and Prophylaxis of Postoperative Thromboembolic Disease in Urological Pelvic Surgery. The Journal of Urology. 1995: 1763–1774.
    CrossRef
  178. Tikkinen KAO, Agarwal A, Craigie S, et al. Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev. 2014; 3: 150.
    CrossRefPubMed
  179. Kutnowski M, Vandendris M, Steinberger R, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. Urol Res. 1977; 5(3): 123–125.
    CrossRefPubMed
  180. Sebeseri O, Kummer H, Zingg E. Controlled prevention of post-operative thrombosis in urological diseases with depot heparin. Eur Urol. 1975; 1(5): 229–230.
    PubMed
  181. Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology. 1992; 39(4): 309–313.
    CrossRefPubMed
  182. Vandendris M, Kutnowski M, Futeral B, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy. Urol Res. 1980; 8(4): 219–221.
    CrossRefPubMed
  183. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318(18): 1162–1173.
    CrossRefPubMed
  184. Nakamura K, Kasraeian A, Yacoub S, et al. The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. Int Braz J Urol. 2007; 33(3): 347–52; discussion 352.
    CrossRefPubMed
  185. Grasso M, Confalonieri S, Blanco S, et al. Preoperative blood donation program and postoperative low molecular weight heparine (LMWH) prophylaxis in patients undergoing radical prostatectomy. Arch Esp Urol. 2009; 62(2): 161–166.
    CrossRefPubMed
  186. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
    CrossRefPubMed
  187. Scarpa RM, Carrieri G, Gussoni G, et al. @RISTOS Study Group. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol. 2007; 51(1): 130–5; discussion 136.
    CrossRefPubMed
  188. Cerruto MA, D'Elia C, Piccoli M, et al. Association between postoperative thromboembolism prophylaxis and complications following urological surgery. Exp Ther Med. 2016; 11(1): 157–163.
    CrossRefPubMed
  189. Coe NP, Collins RE, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery. 1978; 83(2): 230–234.
    PubMed
  190. Koya MP, Manoharan M, Kim SS, et al. Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted? BJU Int. 2005; 96(7): 1019–1021.
    CrossRefPubMed
  191. Cisek LJ, Walsh PC. Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. Urology. 1993; 42(4): 406–408.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note